ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer

Shuai, Shuai*; Liao, Xueyang; Wang, Haixia; Liu, Lusha; Mei, Shiqi; Cao, Jiaxin; Wang, Senming*南方医科大学
Cancer Science2021-10DOI: 10.1111/cas.15000
5被引6阅读
引用收藏
分享

摘要

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (eg, gefitinib) exert potent therapeutic efficacy in non-small-cell lung cancer (NSCLC) harboring EGFR-activating mutations. However, the resistance to EGFR TKIs limits their clinical therapeutic efficacy. TIP30, a newly identified tumor suppressor, appears to be involved in the regulation of cytoplasmic and nuclear EGFR signaling in NSCLC. Our previous study demonstrated that TIP30 regulated EGF-dependent cyclin D1 transcription in human lung adenocarcinoma and suppressed tumorigenesis. In the present study, the involvement of TIP30 in combating gefitinib resistance in NSCLC was determined for the first time in vitro and in vivo. Gain and loss of function studies showed that overexpression of TIP30 effectively sensitized cells to gefitinib in vitro, whereas TIP30 inhibition promoted gefitinib cell resistance. Moreover, TIP30 negatively regulated the activation of the p-AKT and p-MEK signaling pathways in PC9/GR. Importantly, PC9/GR harbored high levels of nuclear EGFR, and overexpression of TIP30 restored irregular EGFR trafficking and degradation from early endosomes to the late endosomes, decreasing the nuclear accumulation of EGFR, which may partly or totally inhibit EGFR-mediated induction of c-Myc transcription. Xenographic tumors induced by overexpression of TIP30 by PC9/GR cells in nude mice were suppressed compared with their original counterparts. Overall, it was revealed that TIP30 overexpression restored gefitinib sensitivity in NSCLC cells and attenuated the cytoplasmic and nuclear EGFR signaling pathways and may be a promising biomarker in gefitinib resistance in NSCLC.

学科与关键词

关键词
EGFRgefitinib resistancenon-small-cell lung cancer (NSCLC)TIP30
相关
加载中…
  • BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
    Yu, Yaya; Xiao, Zhenzhen; Lei, Chenjing; Ma, Changju; Ding, Lina; Tang, Qing; He, Yihan; Chen, Yadong; Chang, Xuesong; Zhu, Yanjuan*; Zhang, Haibo*BMC CANCER, 2023, 23(1): 732.
  • A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells
    Fan, Daping; Yang, Yue; Zhang, Wei*BMC Pulmonary Medicine, 2022, 22(1): 27.被引 4
  • An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging
    Xie, Xin; Zhan, Chenyue; Wang, Jie; Zeng, Fang*; Wu, Shuizhu*Small, 2020, 16(38): 2003451.被引 22
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Science
发表日期
2021-10
卷期
第 112 卷, 第 10 期
页码
4139-4150
DOI
10.1111/cas.15000
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation for Young Scientists of China [81501958]

作者

  • S

    Shuai, Shuai (通讯) (第一作者)

    southern med univ

  • L

    Liao, Xueyang

    southern med univ

查看全部 7 位作者收起作者
  • W

    Wang, Haixia

    southern med univ

  • L

    Liu, Lusha

    southern med univ

  • M

    Mei, Shiqi

    southern med univ

  • C

    Cao, Jiaxin

    southern med univ

  • W

    Wang, Senming (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417